Literature DB >> 31607388

Use of a train-of-four ratio of 0.95 versus 0.9 for tracheal extubation: an exploratory analysis of POPULAR data.

Manfred Blobner1, Jennifer M Hunter2, Claude Meistelman3, Andreas Hoeft4, Markus W Hollmann5, Eva Kirmeier6, Heidrun Lewald6, Kurt Ulm7.   

Abstract

BACKGROUND: The prospective observational European multicentre cohort study (POPULAR) of postoperative pulmonary complications (NCT01865513) did not demonstrate that adherence to the recommended train-of-four ratio (TOFR) of 0.9 before extubation was associated with better pulmonary outcomes from the first postoperative day up to hospital discharge. We re-analysed the POPULAR data as to whether there existed a better threshold for TOFR recovery before extubation to reduce postoperative pulmonary complications in patients who had quantitative neuromuscular monitoring (87% acceleromyography).
METHODS: To identify the optimal TOFR, the complete case cohort of patients with quantitative neuromuscular monitoring (n=3150) was split into several pairs of sub-cohorts related to TOFR values from 0.86 to 0.96; values of 0.97 and higher could not be used as the sub-cohorts were too small. The optimal TOFR was considered to have the lowest P-value from multivariate logistic regression calculated for each of the TOFR values. Data are presented as adjusted absolute risk reduction or median difference with 95% confidence interval.
RESULTS: Extubating patients with TOFR >0.95 rather than >0.9 reduced the adjusted risk of postoperative pulmonary complications by 3.5% (0.7-6.0%) from that reported in POPULAR (11.3%). Increasing the recommended TOFR from 0.9 to 0.95 reduced the adjusted risk by 4.9% (1.2-8.5%). Sub-cohorts resulting from 1:1 propensity score matching revealed that sugammadex had been given in higher doses by 0.30 (0.13-0.48) mg kg-1 in the sub-cohort with TOFR > 0.95.
CONCLUSIONS: A post hoc analysis of patients receiving quantitative monitoring of neuromuscular function suggests that postoperative pulmonary complications are reduced for TOFR > 0.95 before tracheal extubation compared with TOFR > 0.9. TRIAL REGISTRATION NUMBER: NCT01865513.
Copyright © 2019 British Journal of Anaesthesia. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  neuromuscular blocking drug; neuromuscular function monitor; neuromuscular recovery; postoperative pulmonary complications; train-of-four ratio

Year:  2019        PMID: 31607388     DOI: 10.1016/j.bja.2019.08.023

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  11 in total

Review 1.  Reversal of neuromuscular block.

Authors:  J M Hunter
Journal:  BJA Educ       Date:  2020-07-01

2.  Optimizing Reversal of Neuromuscular Block in Older Adults: Sugammadex or Neostigmine.

Authors:  Brandon M Togioka; Katie J Schenning
Journal:  Drugs Aging       Date:  2022-08-08       Impact factor: 4.271

Review 3.  Choice of neuromuscular block reversal agent to reduce postoperative pulmonary complications.

Authors:  Sung-Ae Cho; Tae-Yun Sung
Journal:  Anesth Pain Med (Seoul)       Date:  2022-04-22

4.  Does Sugammadex Reduce Postoperative Airway Failure?

Authors:  Brandon M Togioka; Xinling Xu; Valerie Banner-Goodspeed; Matthias Eikermann
Journal:  Anesth Analg       Date:  2020-07       Impact factor: 5.108

5.  Actual versus ideal body weight dosing of sugammadex in morbidly obese patients offers faster reversal of rocuronium- or vecuronium-induced deep or moderate neuromuscular block: a randomized clinical trial.

Authors:  Jay C Horrow; Manfred Blobner; Wen Li; John Lombard; Marcel Speek; Matthew DeAngelis; W Joseph Herring
Journal:  BMC Anesthesiol       Date:  2021-02-27       Impact factor: 2.217

6.  Recovery of early postoperative muscle strength after deep neuromuscular block by means of ultrasonography with comparison of neostigmine versus sugammadex as reversal drugs: study protocol for a randomised controlled trial.

Authors:  Xuan Wang; Yingyuan Li; Chanyan Huang; Wei Xiong; Qin Zhou; Lijun Niu; Ying Xiao
Journal:  BMJ Open       Date:  2021-02-26       Impact factor: 2.692

7.  Lidocaine combined with magnesium sulfate preserved hemodynamic stability during general anesthesia without prolonging neuromuscular blockade: a randomized, double-blind, controlled trial.

Authors:  Waynice N Paula-Garcia; Gustavo H Oliveira-Paula; Hans Donald de Boer; Luis Vicente Garcia
Journal:  BMC Anesthesiol       Date:  2021-03-27       Impact factor: 2.217

8.  Impact on grafted kidney function of rocuronium-sugammadex vs cisatracurium-neostigmine strategy for neuromuscular block management. An Italian single-center, 2014-2017 retrospective cohort case-control study.

Authors:  M Carron; G Andreatta; E Pesenti; A De Cassai; P Feltracco; F Linassi; M Sergi; C Di Bella; M Di Bello; F Neri; C Silvestre; L Furian; P Navalesi
Journal:  Perioper Med (Lond)       Date:  2022-01-13

9.  Neuromuscular block in patients 80 years and older: a prospective, controlled study.

Authors:  Denis Schmartz; Raouf Sghaier; Paul Bernard; Jean François Fils; Thomas Fuchs-Buder
Journal:  BMC Anesthesiol       Date:  2021-09-13       Impact factor: 2.217

Review 10.  Residual Neuromuscular Blockade and Postoperative Pulmonary Complications: What Does the Recent Evidence Demonstrate?

Authors:  Guy Cammu
Journal:  Curr Anesthesiol Rep       Date:  2020-03-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.